{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:38:44Z","timestamp":1793975924892,"version":"4.8.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Regulatory T (Treg) cells are essential for maintaining peripheral tolerance, preventing autoimmunity, and limiting chronic inflammatory diseases. This small CD4+ T cell population can develop in the thymus and in the peripheral tissues of the immune system through the expression of an epigenetically stabilized transcription factor, FOXP3. Treg cells mediate their tolerogenic effects using multiple modes of action, including the production of inhibitory cytokines, cytokine starvation of T effector (\n                    <jats:italic>e<\/jats:italic>\n                    .\n                    <jats:italic>g<\/jats:italic>\n                    ., IL-2), Teff suppression by metabolic disruption, and modulation of antigen-presenting cell maturation or function. These activities together result in the broad control of various immune cell subsets, leading to the suppression of cell activation\/expansion and effector functions. Moreover, these cells can facilitate tissue repair to complement their suppressive effects. In recent years, there has been an effort to harness Treg cells as a new therapeutic approach to treat autoimmune and other immunological diseases and, importantly, to re-establish tolerance. Recent synthetic biological advances have enabled the cells to be genetically engineered to achieve tolerance and antigen-specific immune suppression by increasing their specific activity, stability, and efficacy. These cells are now being tested in clinical trials. In this review, we highlight both the advances and the challenges in this arena, focusing on the efforts to develop this new pillar of medicine to treat and cure a variety of diseases.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2023.1166135","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T01:06:57Z","timestamp":1681866417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":144,"title":["Opportunities for Treg cell therapy for the treatment of human disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Jeffrey A.","family":"Bluestone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent S.","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Beilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Ramsdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"a006908","DOI":"10.1101\/cshperspect.a006908","article-title":"Historical overview of immunological tolerance","volume":"4","author":"Schwartz","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B2","article-title":"Cell interactions in the induction of tolerance: the role of thymic lymphocytes","volume":"18","author":"Gershon","year":"1970","journal-title":"Immunol"},{"key":"B3","article-title":"Spontaneous development of autoimmune thyroiditis in neonatally thymectomized mice","volume":"34","author":"Kojima","year":"1976","journal-title":"Lab Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/83784","article-title":"Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse","volume":"27","author":"Brunkow","year":"2001","journal-title":"Nat Genet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-75203-5_7","article-title":"Scurfy, the Foxp3 locus, and the molecular basis of peripheral tolerance","volume":"321","author":"Appleby","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ni909","article-title":"An essential role for scurfin in CD4+CD25+ T regulatory cells","volume":"4","author":"Khattri","year":"2003","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801238-3.00116-1","article-title":"Immunological tolerance","author":"Waldmann","year":"2014","journal-title":"Elsevier Reference Module Biomed Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500801","article-title":"Control of regulatory T cell migration, function, and homeostasis","volume":"195","author":"Campbell","year":"2015","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199302000-00027","article-title":"Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. v. dependence of CD4+ suppressor cells on the presence of alloantigen and cytokines, including interleukin 2","volume":"55","author":"Pearce","year":"1993","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095948","article-title":"Tissue tregs","volume":"34","author":"Panduro","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.4366","article-title":"Cutting edge: Autoimmune disease in day 3 thymectomized mice is actively controlled by endogenous disease- specific regulatory T cells","volume":"180","author":"Samy","year":"2008","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198469","article-title":"Induction of colonic regulatory T cells by indigenous clostridium species","volume":"331","author":"Atarashi","year":"2011","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature10434","article-title":"Peripheral education of the immune system by colonic commensal microbiota","volume":"478","author":"Lathrop","year":"2011","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00152","article-title":"Generation and function of induced regulatory T cells","volume":"4","author":"Schmitt","year":"2013","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120822","article-title":"Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo","volume":"209","author":"Yadav","year":"2012","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120914","article-title":"Neuropilin 1 is expressed on thymus- derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ treg cells","volume":"209","author":"Weiss","year":"2012","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/ajt.13456","article-title":"Discarded human thymus is a novel source of stable and long-lived therapeutic regulatory T cells","volume":"16","author":"Dijke","year":"2016","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imr.12160","article-title":"tTregs, pTregs, and iTregs: similarities and differences","volume":"259","author":"Shevach","year":"2014","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01048","article-title":"Foxp3+ T regulatory cells: Still many unanswered questions - a perspective after 20 years of study","volume":"9","author":"Shevach","year":"2018","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3390\/cells10051155","article-title":"Shaping of T cell functions by trogocytosis","volume":"10","author":"Nakayama","year":"2021","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in treg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3004","article-title":"Continuous requirement for the TCR in regulatory T cell function","volume":"15","author":"Levine","year":"2014","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80195-8","article-title":"B7\/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes","volume":"12","author":"Salomon","year":"2000","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/172603a0","article-title":"Actively acquired tolerance of foreign cells","volume":"172","author":"Billingham","year":"1953","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.8094901","article-title":"\"Infectious\" transplantation tolerance","volume":"259","author":"Qin","year":"1993","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00406.x","article-title":"Infectious tolerance and the long-term acceptance of transplanted tissue","volume":"212","author":"Waldmann","year":"2006","journal-title":"Immunol Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020394","article-title":"Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells","volume":"196","author":"Jonuleit","year":"2002","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000484295","article-title":"'Repair' treg cells in tissue injury","volume":"43","author":"Zhang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.021","article-title":"A distinct function of regulatory T cells in tissue protection","volume":"162","author":"Arpaia","year":"2015","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"104160","DOI":"10.1016\/j.cellimm.2020.104160","article-title":"Regulatory T cells: Master thieves of the immune system","volume":"355","author":"Akkaya","year":"2020","journal-title":"Cell Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.9.5852","article-title":"Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis","volume":"177","author":"Uhlig","year":"2006","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200839073","article-title":"Curing CNS autoimmune disease with myelin- reactive Foxp3+ treg","volume":"39","author":"Stephens","year":"2009","journal-title":"Eur J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/art.21195","article-title":"Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells","volume":"52","author":"Morgan","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nm1688","article-title":"Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes","volume":"14","author":"Joffre","year":"2008","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1927","article-title":"Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke","volume":"15","author":"Liesz","year":"2009","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002740","article-title":"Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice","volume":"3","author":"Banerjee","year":"2008","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/ijms24021752","article-title":"Treg therapy for the induction of immune tolerance in transplantation\u2013not lost in translation","volume":"24","author":"Pilat","year":"2023","journal-title":"Intl J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28459","article-title":"A pilot study of operational tolerance with a regulatory T-cell- based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92865","article-title":"T Cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12085","article-title":"Role of regulatory T cells during virus infection","volume":"255","author":"Veiga-Parga","year":"2013","journal-title":"Immunol Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2008.05.011","article-title":"Paradoxical roles of Foxp3+ T cells during infection: from regulators to regulators","volume":"3","author":"Belkaid","year":"2008","journal-title":"Cell Host Microbe"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2011.00098","article-title":"Chronic inflammation in cancer development","volume":"2","author":"Multhoff","year":"2012","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648408","article-title":"Low-dose IL-2 therapy in autoimmune and rheumatic diseases","volume":"12","author":"Gra\u00dfhoff","year":"2021","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202659","article-title":"TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory t. cell phenotype in the inflammatory environment","volume":"190","author":"Chen","year":"2013","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3432","article-title":"Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis","volume":"20","author":"Komatsu","year":"2014","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.1191996","article-title":"Stability of the regulatory T cell lineage in vivo","volume":"329","author":"Rubtsov","year":"2010","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/art.40737","article-title":"Adoptive treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall'Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B57","unstructured":"Caladrius biosciences reports top-line data for the phase 2a Sanford project: T-Rex trial of CLBS03 for recent onset type 1 diabetes2019"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e147474","DOI":"10.1172\/jci.insight.147474","article-title":"The effect of low- dose IL-2 and treg adoptive cell therapy in patients with type 1 diabetes","volume":"6","author":"Dong","year":"2021","journal-title":"JCI Insight"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory crohn's disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-306919","article-title":"Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for crohn's disease","volume":"65","author":"Canavan","year":"2016","journal-title":"Gut"},{"key":"B61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/gutjnl-2022-327075","article-title":"Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis","volume":"72","author":"Voskens","year":"2023","journal-title":"Gut"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12029","article-title":"Clinical application of regulatory T cells in type 1 diabetes","volume":"14","author":"Marek-Trzonkowska","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants","volume":"17","author":"Chandran","year":"2017","journal-title":"Am J Transplant"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","article-title":"A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci Rep"},{"key":"B66","doi-asserted-by":"publisher","first-page":"m3734","DOI":"10.1136\/bmj.m3734","article-title":"Regulatory T cells for minimising immune suppression in kidney transplantation: phase I\/IIa clinical trial","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061864","article-title":"Transplantation without overimmunosuppression (TWO) study protocol: A phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients","volume":"12","author":"Brook","year":"2022","journal-title":"BMJ Open"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6927","article-title":"Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation","volume":"7","author":"Safinia","year":"2016","journal-title":"Oncotarget"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo2628","article-title":"Selective decrease of donor-reactive tregs after liver transplantation limits treg therapy for promoting allograft tolerance in humans","volume":"14","author":"Tang","year":"2022","journal-title":"Sci Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.893576","article-title":"A novel GMP protocol to produce high-quality treg cells from the pediatric thymic tissue to be employed as cellular therapy","volume":"13","author":"Bernaldo-de-Quir\u00f3s","year":"2022","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003219","article-title":"First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA- matched siblings","volume":"5","author":"MacMillan","year":"2021","journal-title":"Blood Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.228","article-title":"Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation","volume":"2018","author":"Hamilton","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127244","article-title":"Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients","volume":"4","author":"Meyer","year":"2019","journal-title":"JCI Insight"},{"key":"B75","doi-asserted-by":"publisher","first-page":"8348","DOI":"10.1038\/s41598-022-12407-x","article-title":"Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib","volume":"12","author":"And\u00fajar-S\u00e1nchez","year":"2022","journal-title":"Sci Rep"},{"key":"B76","unstructured":"MeyerE\n          2021"},{"key":"B77","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.26375","article-title":"Tregs attenuate peripheral oxidative stress and acute phase proteins in ALS","volume":"92","author":"Beers","year":"2022","journal-title":"Ann Neurol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000465","article-title":"Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in- human study","volume":"5","author":"Thonhoff","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.10.009","article-title":"Allogeneic cord blood regulatory T cells can resolve lung inflammation","volume":"25","author":"Lyu","year":"2023","journal-title":"Cytotherapy"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744763","article-title":"Polyclonal regulatory T cell manufacturing under cGMP: A decade of experience","volume":"12","author":"Balcerek","year":"2021","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments tregs yet transiently impairs \u03b2-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-700849","article-title":"Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells","volume":"128","author":"Leclerc","year":"2016","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783282","article-title":"IL- 6 and TNF\u03b1 drive extensive proliferation of human tregs without compromising their lineage stability or function","volume":"12","author":"Skartsis","year":"2021","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00611","article-title":"Human regulatory T cells from umbilical cord blood display increased repertoire diversity and lineage stability relative to adult peripheral blood","volume":"11","author":"Motwani","year":"2020","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A rapamycin- based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0050-5","article-title":"Treatment of graft-versus-host disease with naturally occurring T regulatory cells","volume":"27","author":"Trzonkowski","year":"2013","journal-title":"BioDrugs"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00307-7","article-title":"TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential","volume":"28","author":"Poorebrahim","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0831","article-title":"Discovery of a conditionally activated IL-2 that promotes antitumor immunity and induces tumor regression","volume":"10","author":"Nirschl","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/mi.2013.73","article-title":"New targets for mucosal healing and therapy in inflammatory bowel diseases","volume":"7","author":"Neurath","year":"2014","journal-title":"Mucosal Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/ajt.14936","article-title":"Tailoring the homing capacity of human tregs for directed migration to sites of Th1-inflammation or intestinal regions","volume":"19","author":"Hoeppli","year":"2019","journal-title":"Am J Transplant"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03136","article-title":"Molecular mechanisms controlling Foxp3 expression in health and autoimmunity: From epigenetic to post-translational regulation","volume":"10","author":"Colamatteo","year":"2020","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1654","article-title":"Immunotherapy: Building a bridge to a cure for type 1 diabetes","volume":"373","author":"Bluestone","year":"2021","journal-title":"Science"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.565518","article-title":"The next frontier of regulatory T cells: Promising immunotherapy for autoimmune diseases and organ transplantations","volume":"11","author":"Terry","year":"2020","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.015","article-title":"Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier","volume":"142","author":"Esensten","year":"2018","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1166135\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T01:07:08Z","timestamp":1681866428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1166135\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":97,"alternative-id":["10.3389\/fimmu.2023.1166135"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1166135","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"article-number":"1166135"}}